Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Treatment: Once patients are diagnosed with grade II\~IV acute GVHD, the combination therapy should be initiated as soon as possible. 1. Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid every one or two weeks according to patient's response. 2. Ruxolitinib 5\~10mg bid po for at least 28 days. If patient's ANC\<0.5×10e9/L or PLT\< 20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher than 20×10e9/L. Indication for stopping Ruxolitinib treatment: 1. No response after ruxolitinib treatment for 28 days. 2. Develop life-threatening complication. 3. ANC\<0.5×10e9/L or PLT\< 20×10e9/L. Indication for second line acute GVHD treatment: 1. deterioration of acute GVHD in 3 days 2. no response after 7 days 3. no complete remission after 2 weeks. Suggestions of second line therapy: Basiliximab 20mg, d1, d4, d8.